MindBio Therapeutics Delivers Edge AI Kiosk Prototypes for Workplace Impairment Detection

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) has completed and delivered its first Edge AI Intoxication and Fatigue Detection Kiosk prototypes, marking a significant step in commercializing voice-based impairment detection technology for workplace safety. The kiosks utilize artificial intelligence to analyze short voice samples for over 140 acoustic markers linked to potential alcohol, drug, or fatigue-related impairment, with models trained on more than 50 million data points. These prototypes are now entering testing, validation, and data-analysis phases involving industry participants, speech specialists, and software engineers as the company refines its predictive models and assesses real-world performance.

MindBio is targeting safety-sensitive industries such as mining, aviation, construction, transportation, and law enforcement, where large workforces and operational risks make conventional breath, saliva, urine, and laboratory testing costly and time-consuming. The company's approach aims to provide rapid, scalable, and less invasive initial screening, with individuals flagged for potential impairment able to undergo additional evaluation using established testing protocols. This innovation could transform workplace safety by enabling frequent, non-intrusive checks that reduce accidents and liability.

The importance of this announcement lies in its potential to address critical safety gaps in high-risk industries. Traditional impairment testing methods are often impractical for large-scale, routine screening due to cost, time, and privacy concerns. MindBio's Edge AI kiosks offer a faster, more scalable alternative that could be deployed at entry points, break rooms, or vehicle check-ins. If successful, the technology could significantly lower the incidence of workplace accidents caused by impaired employees, saving lives and reducing economic losses.

For more details, the full article is available at https://ibn.fm/R2OqM. MindBio Therapeutics is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company is developing an enterprise platform including Edge-AI kiosks with bespoke hardware and software for various enterprise environments. More information can be found at www.MindBioTherapeutics.com.

As the prototypes undergo testing, the outcomes will determine the technology's accuracy and reliability in real-world settings. Successful validation could open doors to widespread adoption across industries, positioning MindBio as a leader in AI-driven safety solutions. The company's focus on voice-based detection also offers a non-invasive method that respects worker privacy while enhancing safety protocols. This development underscores the growing role of artificial intelligence in occupational health and safety, with implications for regulatory standards and industry practices.